Earnings To Watch: Medifast (MED) Reports Q4 Results Tomorrow

Wellness company Medifast (NYSE:MED) will be reporting results this Tuesday after the bell. Here’s what to expect.

Medifast met analysts’ revenue expectations last quarter, reporting revenues of $89.41 million, down 36.2% year on year. It was a very strong quarter for the company, with EPS guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.

This quarter, analysts are expecting Medifast’s revenue to decline 40% year on year to $71.4 million, a further deceleration from the 37.7% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.82 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medifast has missed Wall Street’s revenue estimates three times over the last two years.

Looking at Medifast’s peers in the personal care segment, some have already reported their Q4 results, giving us a hint as to what we can expect. e.l.f. Beauty delivered year-on-year revenue growth of 37.8%, beating analysts’ expectations by 6.4%, and Estée Lauder reported revenues up 5.6%, in line with consensus estimates. e.l.f. Beauty traded down 9.2% following the results while Estée Lauder was also down 16.8%.

There has been positive sentiment among investors in the personal care segment, with share prices up 3.7% on average over the last month. Medifast is down 7.6% during the same time and is heading into earnings with an average analyst price target of $15 (compared to the current share price of $10.78).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.